Course syllabus

Due to COVID-19, the course may be given as a distance course with lectures and seminars via ZOOM. The decision will be taken when the time approaches.

 

Drug Development BIO523/KMG046

 

Programs:                  Molecular Biology and Genomics/Systems Biology programs (GU), Biotechnology program (Chalmers)

 

Place in program:     Year 4/5, optional

 

Number of students: No limitation

 

Course leader:           Prof. Margit Mahlapuu, Department of Chemistry and Molecular Biology (CMB), Göteborg University; Medicinaregatan 9C, 413 90 Göteborg/ Box 462  405 30 Göteborg

Phone: 0706310109

E-mail: margit.mahlapuu@gu.se

 

Changes in the schedule and other messages regarding the course will be distributed through e-mail and/or posted at Canvas. Handouts will likewise be available at Canvas.

 

Length:                       7.5 ECTS

 

Prerequisites:            For admission to the course, approved courses of 120 credits in the field of natural science are required, of which at least 15 credits must be within the main subject molecular biology and 15 credits in the main subject chemistry or equivalent. In addition, applicants must prove their knowledge of English.

 

Time:                          Fall term 2021

 

Aim:                            This course shall focus on a building an overall understanding of the discovery and development of novel pharmaceuticals (drug discovery/development), covering a wide spectrum of target selection, lead discovery/optimization, nonclinical in vitro/in vivo safety and efficacy studies, clinical trials, and market authorization. Examples are given of existing drugs, how they have been developed, and their mechanisms of action. The course is mostly theoretical, but in certain parts, practical demonstrations can also be included.

 

Literature:                 Scientific review papers, a separate list will provided by individual lecturers via Canvas.

                                   

Exam:                         Ordinary examination 14th of Jan 2022 at 10.00-14.45 (location: R. Sandberg), re-examination 21st of Feb 2022 09.00-15.00

 

Items in course:         The course is based on lectures and study visits with demonstrations. 

 

Teachers:                  

Margit Mahlapuu margit.mahlapuu@gu.se

Per Sunnerhagen per.sunnerhagen@cmb.gu.se

Marica Ericson marica.ericson@chem.gu.se

Morten Grötli grotli@chem.gu.se

Göran Karlsson goran.karlsson@nmr.gu.se

Marc Pilon marc.pilon@cmb.gu.se

Björn Löwenadler bjorn.lowenadler@toleranzia.com

Lorna Fletcher lorna.fletcher@ventures.gu.se
Camilla Björn camilla.bjorn@ri.se

Pawel Baranczewski pawel.baranczewski@farmaci.uu.se

Thomas Lundbäck thomas.lundback@astrazeneca.com

Joakim Håkansson joakim.hakansson@ri.se

Ann-Charlotte Rosendahl ann-charlotte.rosendahl@sobrera.com

Pär Matsson par.matsson@gu.se

Emmelie Cansby emmelie.cansby@gu.se

Daniel Bojar <daniel.bojar@gu.se>

 

 

 

 

 SCHEDULE, Drug development

 

Premises

Lectures:  The lecture rooms are at Medicinaregatan 9 or 11, Gothenburg, as specified in the table below. NMR Center: Swedish NMR Center in Gothenburg, Medicinaregatan 5C; seminar room is just inside the main entrance. Rooms are equipped with projectors.  

 

                       

Day	Times	Room	Lecture/demonstration
M 15/11	13.15 – 15.00	1411, Medg 11	Overview of the process of drug development (Margit Mahlapuu, CMB, GU)
	15.15 – 17.00	1411, Medg 11	Genetic model organisms: Yeast (Per Sunnerhagen, CMB, GU)
Th 18/11	8.00 – 9.45	2421 Å Göransson/ K2320 C Kylberg	Genetic model organisms: C. elegans (Marc Pilon, CMB, GU)
	10.00 – 11.45	K2320 C Kylberg	Transgenic mice in drug discovery and development (Margit Mahlapuu, CMB, GU)
M 22/11	13.15 – 15.00	1405 B Folkow	High throughout screening: assay development, validation, and platform (Thomas Lundbäck, AstraZeneca)
	15.15 – 17.00	2046 N Nilsson	High throughout screening: assay development, validation, and platform (Thomas Lundbäck, AstraZeneca)
Th 25/11	8.00 – 9.45	P2240 W Sjölander/ 1737 IÖstholm	Protein as a target molecule: rational drug design (Göran Karlsson, NMR center, GU)
	10.00 – 11.45	1737 IÖstholm	NMR-based methods in drug discovery (Göran Karlsson, NMR center, GU)
M 29/11	13.15 – 15.00	2256 R Sandberg	Design of pharmaceuticals directed against proteins with known activity (Morten Grøtli, CMB, GU)
	15.15 – 17.00	2256 R Sandberg	Advanced optical microscopy as a tool in drug development (Marica Ericson, CMB, GU)
Th 2/12	8.00 – 9.45	2256 R Sandberg	Peptide and protein drugs (Margit Mahlapuu, CMB, GU; Björn Löwenadler, Toleranzia)
	10.00 – 11.45	17737 Östholm	Medical device: differences compared to pharmaceuticals (Joakim Håkansson, RISE)
M 6/12	13.15 – 15.00	2256 R Sandberg	Antisense therapy (Pär Matsson, Dept. of Pharmacology, GU and OligoNova Hub, Oligonucleotide Therapeutics)
	15.15 – 17.00	Lecture via zoom (Pawel in placed in Stockholm), the zoom link will be distributed	Pharmacokinetics, ADME, drug metabolism (Pawel Baranczewski, SciLifeLab, Uppsala)
Th 9/12	8.00 – 9.45	2403 Sandels	Intellectual property and financing aspects of early drug discovery (Lorna Fletcher, GU Ventures)
	10.00 – 11.45	2046 N Nilsson	Development of novel anti-infectives: opportunities and vulnerabilities (Camilla Björn, RISE)
M 13/12	13.15 – 15.00	1412, Medg 11	New medicines: market access and customer perspective (45 min; Ann-Charlotte Rosendahl, Sobrerea) AI in drug discovery (45 min; Daniel Bojar, GU)
	15.15 – 17.00		Vacant
Th 16/12	8.00 – 9.45		Vacant
	10.00 – 11.45		Vacant